



COVID-19 Vaccines and Vaccination

Collection Editors:

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, University of Georgia,
Athens, GA 30602, USA

Dr. Scott Anthony

National Institute of Allergy and
Infectious Diseases (NIAID),
Frederick, MD, USA

Message from the Collection Editors

Dear Associates,

There are >200 vaccine candidates for COVID-19 being developed. Of these, >50 candidate vaccines are in clinical trials. It is expected that the different vaccines in development will secure the chance that one or more will be efficacious and safe.

There are three approaches to vaccine design:

- (1) whole virus,
- (2) part of the virus that triggers immunity, or
- (3) viral genetic material.

This Collection on “COVID-19 Vaccine Development and Vaccination” will highlight the recent effort to develop, test, and use vaccines on individuals with promising vaccine platforms against SARS-CoV-2. These approaches may include a whole virus approach (live-attenuated vaccine, inactivated vaccine, or viral vector vaccine), a subunit approach, or genetic approaches that include nucleic acid vaccines.

Prof. Dr. Ralph Tripp
Dr. Steven B. Bradfute
Dr. Scott Anthony
Collection Editors ,





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com